Sign in

    Anita Dushyanth

    Research Analyst at Zacks Investment Research

    Anita Dushyanth's questions to TITAN PHARMACEUTICALS (TTNP) leadership

    Anita Dushyanth's questions to TITAN PHARMACEUTICALS (TTNP) leadership • Q4 2019

    Question

    Anita Dushyanth of Zacks Investment Research asked about the addressable market for Probuphine within the veteran population following its addition to the federal supply schedule. She also inquired about European pricing strategy, the 2020 target for active prescribers, prescription approval rates, and performance metrics for the physician portal.

    Answer

    EVP and Chief Commercial Officer Dane Hallberg explained that veterans are affected by Opioid Use Disorder (OUD) at a 50% higher rate than the general population, though specific market size numbers are not published. President and CEO Sunil Bhonsle stated that European pricing is expected to be about 40% lower than in the U.S. and that the company is still working toward its goal of 500 active prescribers. Hallberg added that prescription approval rates are high, upwards of 70%, with 94% medical benefit coverage, but physician portal metrics are not publicly disclosed.

    Ask Fintool Equity Research AI

    Anita Dushyanth's questions to Phio Pharmaceuticals (PHIO) leadership

    Anita Dushyanth's questions to Phio Pharmaceuticals (PHIO) leadership • Q3 2018

    Question

    Anita Dushyanth from Zacks Small Capital Research inquired about the company's cash burn rate, future expense projections, and the strategic priorities for newly appointed President and COO, Dr. Gerrit Dispersyn. She also asked for a timeline on expected data from the Karolinska Institute collaboration and for a more detailed explanation of how the sd-rxRNA technology enhances the activity of Natural Killer (NK) cells for adoptive cell therapy.

    Answer

    Caitlin Kontulis, Senior Director of Finance, stated the quarterly cash burn is expected to remain around $2 million before increasing in late 2019 for clinical trial preparations, with the current cash runway extending into the second half of 2020. Dr. Gerrit Dispersyn, President and COO, outlined his focus on expanding R&D collaborations in immuno-oncology, expecting more pipeline products. He projected initial data from the Karolinska collaboration in Q1 2019. He also detailed how sd-rxRNA enhances NK cells by overcoming tumor suppression mechanisms without genetic modification, which is compatible with creating 'off-the-shelf' frozen cell therapies.

    Ask Fintool Equity Research AI

    Anita Dushyanth's questions to Phio Pharmaceuticals (PHIO) leadership • Q2 2018

    Question

    Anita Dushyanth from Zacks Small Capital Research asked about the level of interest in RXI-109 following the recent FDA approval of the first RNAi therapeutic, what insights the approval provides for RXi's pipeline, and how RNAi modifies T-cell receptors.

    Answer

    Chief Development Officer Gerrit Dispersyn stated the FDA approval is a major milestone that validates the RNAi space and helps in partner discussions. President and CEO Geert Cauwenbergh explained that RNAi prevents protein production, like the PD-1 receptor, by blocking its specific messenger RNA. Gerrit Dispersyn added that while the initial focus is on the proven PD-1 target, the platform allows for future combination therapies targeting the tumor microenvironment.

    Ask Fintool Equity Research AI

    Anita Dushyanth's questions to Sintx Technologies (SINT) leadership

    Anita Dushyanth's questions to Sintx Technologies (SINT) leadership • Q2 2016

    Question

    Anita Dushyanth from Zacks Investment Research asked if clinical trials would be required for CFDA clearance in China under the Weigao agreement and inquired about the potential applications, target audience, and initial sales regions for silicon nitride in the dental market.

    Answer

    Chairman and CEO Dr. Sonny Bal expressed his hope that additional trials for Chinese or Japanese FDA approval would not be necessary, given the extensive existing clinical data from over 30,000 implants and multiple studies. CFO Ty Lombardi added that while they are hopeful, the final determination is pending submission. Regarding dental applications, Dr. Bal described it as a pipeline project targeting the dental implant market, leveraging silicon nitride's superior strength, bone in-growth, and unique antimicrobial properties against oral bacteria, which he called a 'perfect implant for dental applications'.

    Ask Fintool Equity Research AI

    Anita Dushyanth's questions to Sintx Technologies (SINT) leadership • Q1 2016

    Question

    Anita Dushyanth of Zacks Investment Research asked about the potential requirement for clinical trials for the Chinese FDA (CFDA) approval and inquired about the company's financial objectives for 2016.

    Answer

    CFO Ty Lombardi responded that it is still too early to determine if a clinical trial will be required by the CFDA. He stated they are working with their partner, Weigao, to prepare the submission and hope their existing body of data will accelerate the process. Chairman and CEO Dr. Sonny Bal added that with over 25,000 implants in the field over eight years without implant-related failures, they have substantial clinical history to support their application. The question about 2016 financial objectives was not directly addressed with specific targets.

    Ask Fintool Equity Research AI

    Anita Dushyanth's questions to TENAX THERAPEUTICS (TENX) leadership

    Anita Dushyanth's questions to TENAX THERAPEUTICS (TENX) leadership • Q1 2016

    Question

    Anita Dushyanth of Zacks Investment Research, Inc. asked about the benefits of recent investments in trial support initiatives, the status of licensing agreements, and the competitive threat of camptothecin for septic shock.

    Answer

    CEO John Kelley explained that investments in a field-based medical science liaison have directly boosted patient recruitment for the LEVO-CTS trial. He added that market research on septic shock and LCOS is informing their commercial strategy. Kelley clarified that Tenax holds the North American license for levosimendan and is evaluating other opportunities. He also noted he was unfamiliar with the competitor drug camptothecin but highlighted levosimendan's specific mechanism of supporting organ function in septic shock.

    Ask Fintool Equity Research AI